Arrowhead Pharma target price raised on plozasiran clinical win; shares jump 19%

ARWR Arrowhead Pharmaceuticals Inc

$62.75 +3.31%

View chart & analysis →

INTC -2.22% TXN -1.55% IONS +4.57%

1. 1Arrowhead Pharmaceuticals (ARWR) shares surged 19% the previous day and added another 1.5% in extended trading.
2. 2Chardan analyst Kei Nakaye raised the price target from $90 to $115 and reiterated a Buy rating, noting that plozasiran met its primary endpoints in both Phase trials for severe hypertriglyceridemia.
3. 3Arrowhead plans to submit an FDA application for this indication by the end of 2026, and upon approval it would compete directly with Ionis Pharmaceuticals' (IONS) olezarsen, which received FDA approval last month.

Source Stocktwits +3 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →